Hetland G, Talgö G J, Fagerhol M K
Institute of Immunology and Rheumatology, National Hospital, Oslo, Norway.
Mol Pathol. 1998 Jun;51(3):143-8. doi: 10.1136/mp.51.3.143.
To determine whether the chemotaxins C5a and formyl peptide (fMLP) can stimulate the release of calprotectin, the major leucocyte protein of polymorphonuclear neutrophils (PMN).
A dose response curve for the uptake of 125I labelled rC5a and fMLP in PMN was determined by radioimmunoassay. The unlabelled chemotaxins were then incubated with PMN and the concentration of calprotectin in PMN lysates and supernatants was measured by an enzyme immunoassay.
Both rC5a and fMLP induced release of calprotectin from PMN in a dose dependent manner as determined by a reduction in intracellular calprotectin concentration. A minimum of approximately 10% of total PMN calprotectin was retained at concentrations of 10-100 nM of rC5a and 0.1-10.0 nM of fMLP. Antibodies to C5a reduced the rC5a mediated release of calprotectin, and the fMLP antagonist N-t-Boc-MLP inhibited the fMLP induced calprotectin release. Because receptors for rC5a (CD88) and fMLP are G protein coupled and thought to be pertussis toxin sensitive, PMN were incubated with this toxin before the experiments. The toxin was found to reduce uptake of rC5a by the cells and to inhibit rC5a and fMLP mediated calprotectin release.
rC5a and fMLP mediate release of calprotectin from PMN in vitro. This effect might be important during human infections in vivo.
确定趋化因子C5a和甲酰肽(fMLP)是否能刺激钙卫蛋白的释放,钙卫蛋白是多形核中性粒细胞(PMN)的主要白细胞蛋白。
通过放射免疫测定法确定PMN对125I标记的rC5a和fMLP摄取的剂量反应曲线。然后将未标记的趋化因子与PMN一起孵育,并通过酶免疫测定法测量PMN裂解物和上清液中钙卫蛋白的浓度。
如通过细胞内钙卫蛋白浓度降低所确定的,rC5a和fMLP均以剂量依赖性方式诱导PMN释放钙卫蛋白。在rC5a浓度为10 - 100 nM和fMLP浓度为0.1 - 10.0 nM时,至少约10%的PMN总钙卫蛋白被保留。抗C5a抗体减少了rC5a介导的钙卫蛋白释放,并且fMLP拮抗剂N - t - Boc - MLP抑制了fMLP诱导的钙卫蛋白释放。由于rC5a(CD88)和fMLP的受体是G蛋白偶联的,并且被认为对百日咳毒素敏感,因此在实验前将PMN与该毒素一起孵育。发现该毒素可减少细胞对rC5a的摄取,并抑制rC5a和fMLP介导的钙卫蛋白释放。
rC5a和fMLP在体外介导PMN释放钙卫蛋白。这种作用在体内人类感染期间可能很重要。